Latest Glycoproteins Stories
ROCHESTER, N.Y., Dec. 3, 2014 /PRNewswire/ -- Vaccinex Inc. announced today that Dr.
MAB242P, the most recently developed antibody, is the first MBS antibody to recognize both GI and GII strains of norovirus.
PhosImmune and PureMHC Working Together On Immunotherapies for Cancer CHARLOTTESVILLE, Va. and AUSTIN, Texas, Oct. 22, 2014 /PRNewswire/ -- PhosImmune Inc.
Management Responds To Inquiries Concerning Discovery Capabilities For Anti-Ebola Treatments SAN DIEGO, Oct. 21, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc.
PLYMOUTH, Minn., Oct.
-- CIAO!(TM) Technology Maximizes Selectivity of Conditionally Active Antibodies -- SAN DIEGO, Oct.
AACHEN, Germany, ATLANTA and SHANGHAI, September 30, 2014 /PRNewswire/ -- According to the latest Pivotal Scientific Antibody Market Report [http://www.pivotalscientific.com/antibody-market-report/antibody-market-report-6-01-08-2014